Propranolol for Misophonia
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorBloom Mental Health, LLC
About this trial
The primary goal of this study is to investigate whether a one-time dose of 20 mg oral propranolol can temporarily reduce the adverse emotional and physical symptoms triggered by misophonia.
The secondary goals of this study are:
1. Determine potential predictors of response to propranolol treatment, including demographic factors, baseline symptom severity, psychometric instrument item responses, and physiological characteristics. 2. Evaluate the safety and tolerability of propranolol in individuals with misophonia.
Eligibility criteria
Qualifiers
Age 18-65.
Able to complete study visit(s) in Littleton, CO.
Able to give informed consent.
Participant reports clinically significant misophonia symptoms, as determined by answers on the standardized "Misophonia Trigger Screening Questions for Participants" form (described separately in the protocol). Specifically, participants must demonstrate relevant misophonia trigger responses that meet pre-specified minimum severity criteria detailed on this form.
Disqualifiers
Current use of scheduled propranolol for any condition.
cardiogenic shock
sinus bradycardia (<50 bpm)
greater than first degree heart block
Trial design
Treatments tested in this trial
- propranolol
- Placebo
Treatment groups
20 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov